Mendoza-González C

Idioma: Español
Referencias bibliográficas: 20
Paginas: 209-213
Archivo PDF: 116.64 Kb.

RESUMEN

La mortalidad del infarto agudo del miocardio (IAM) ha disminuido con la introducción de las nuevas estrategias de reperfusión; de forma paralela, el número de pacientes (pts) con disfunción ventricular izquierda ha aumentado. Ésta es una población especial de pts con riesgo de sufrir un evento de muerte súbita (MS). Este hecho requiere de un adecuado proceso de estratificación del riesgo para MS que esta población tiene y con el que se pueden establecer las medidas de prevención primaria y secundaria necesarias para disminuir la mortalidad de estos pts. Se revisan a continuación las características clínicas de la población con antecedente de IAM y/o disfunción ventricular izquierda que pueden sugerir la indicación del implante de un desfibrilador automático implantable (DAI).

REFERENCIAS (EN ESTE ARTÍCULO)

1. PRIORI S, ALIOT E, BLOMSTROM-LUNDQVIST C, BOSSAERT L, BREITHARDT G, BRUGADA P, CAMM A, CAPPATO R, COBBE S, DI MARIO C, MARON B, MCKENNA W, PEDERSEN A, RAVENS U, SCHWARTZ P, TRUSZ-GLUZA M, VARDAS P, WELLENS H, ZIPES DP. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-1450.

2. VREEDE-SWAGEMAKERS JJ, GORGELS A, DUBOIS-ARBOUW WI, VAN REE JW, DAEMEN MJ, HOUBEN LG, WELLENS HJ: Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30: 1500-1505.

3. STEVEN N, SINGH, FLETCHER RD, GROSS FISHER S, SINGH BN, LEWIS HD, DEEDWANIA PC, MASSIE BM, COLLING C, LAZZERI D, for The Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. CHF-STAT. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.

4. DOVAL HC, NUL DR, GRANCELLI HO, PERRONE SV, BORTMAN GR, CURIEL R: Grupo de Estudio de la Sobrevida en la IC en Argentina (GESICA). Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 489-490.

5. COOPER HA, DRIES DL, DAVIS CE, SHEN YL, DOMANSKI AND MJ: Diuretics and Risk of Arrhythmic Death in Patients With Left Ventricular Dysfunction. Circulation 1999; 100: 1311-1315.

6. GOLDMAN S, JOHNSON G, COHN JN, CINTRON G, SMITH R, FRANCIS G: The V-HeFT VA Cooperative Studies Group. The Vasodilator-Heart Failure Trials. Mechanism of death in heart failure. Circulation 1993; 87: VI24-VI31.

7. MERIT-HF: Investigators group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.

8. CIBIS-II Investigators group. The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. The Lancet 1999; 353: 9-13.

9. PACKER M, BRISTOW MR, COHN JN, COLUCCI, FOWLER MB, GILBERT EM, SHUSTERMAN NH: The U.S. Carvedilol Heart Failure Study Group. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 1996; 334: 1349-1355.

10. SWEENEY MO: Sudden Death in Heart Failure Associated with Reduced Left Ventricular Function: Substrates, Mechanisms, and EvidenceBased Management, Part I. PACE. 2001; 24: 871-888.

11. LOMBARDI G, GALLAGHER J, GENNIS P. Outcome of out-of-hospital cardiac arrest in New York City. The Pre-Hospital Arrest Survival Evaluation (PHASE) Study. JAMA. 1994;271:678-683.

12. SHEN WK, HAMMILL SC: Survivors of acute myocardial infarction: who is at risk for sudden cardiac death? Mayo Clin Proc 1991; 66: 950-962.

13. BUXTON A, LEE KL, DICARLO L, GOLD MR, GREER GS, PRYSTOWSKY EN, O’TOOLE MF, TANG A, FISHER JD, COROMILAS J, TALAJIC M, HAFLEY G: The Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic Testing to Identify Patients with Coronary Artery Disease Who Are at Risk for Sudden Death. N Engl J Ned 2000; 342: 1937-1940.

14. KØBER L, TORP-PEDERSEN C, CARLSEN JE, BAGGER H, ELIASEN P, LYNGBORG K, VIDEBÆK J, COLE DS, AUCLERT L, PAULY NC, ALIOT E, PERSSON S, CAMM AJ, for The Trandolapril Cardiac Evaluation (TRACE) study group. A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 1995; 333: 1670-1676.

15. DARGIE HJ: The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-90.

16. JULIAN DG, CAMM AJ, FRANGIN G, JANSE MJ, MU- ÑOZ A, SCHWARTZ PJ, SIMON P: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.

17. MOSS AJ, HALL WJ, CANNOM DS, DAUBERT JP, HIGGINS SL, KLEIN H, LEVINE JH, SAKSENA S, WALDO AL, WILBER D, BROWN MW, HEO M, for The Multicenter Automatic Defibrillator Implantation Trial Investigators MADIT. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. N Engl J Med 1996; 335: 1933-40.

18. BUXTON AE, ELLISON KE, KIRK MM, FRAIN B, KOO C, GANDHI G Y KHOUZAM S: Primary Prevention of Sudden Cardiac Death: Trials in Patients with Coronary Artery Disease. J of Interventional Cardiac Electrophysiol 2003; 9: 203-206.

19. MOSS AJ, ZAREBA W, HALL WJ, KLEIN H, WILBER DJ, CANNOM DS, DAUBERT JP, HIGGINS SL, BROWN MW, ANDREWS ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. N Engl J Med. 2002; 346: 877-883.

20. GREGORATOS G, GIBBONS RJ, ANTMAN EM, ABRAMS J, EPSTEIN AE, FREEDMAN RA, HAYES DL, HLATKY MA, KERBER RE, NACCARELLI GV, SCHOENFELD MH, SILKA MJ, WINTERS SL: ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2002. J Am Coll Cardiol 2002; 40: 1703-1719.